Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

NCT03851614 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Mismatch Repair Proficient Colorectal Cancer
Pancreatic Adenocarcinoma
Leiomyosarcoma

Interventions

BIOLOGICAL: Durvalumab
DRUG: Olaparib
DRUG: Cediranib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]